Hi-Tech Pharmacal Co. Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hi-Tech Pharmacal Co. Inc.
The VMIC has neither confirmed or denied to Scrip a report from the Financial Times that the project, which has received many millions of taxpayer money, is about to be sold off privately, with Oxford BioMedica mentioned as a potential bidder.
The EMA is going all out to maximize coverage of the EU population with both vaccines and treatments for COVID-19.
Coronavirus Notebook: Molnupiravir EU Approval Likely By Year End, Special CHMP Session Due On Comirnaty in 5 to 11-year-olds
The EMA is assessing the Janssen vaccine as a booster, and Switzerland is evaluating the use of the Pfizer/BioNTech and Moderna COVID-19 vaccines in younger age groups. The WHO has announced the first voluntary global license on a COVID-19 antibody detection technology.
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
- Other Names / Subsidiaries
- ECR Pharmaceuticals